This Market Event Summary provides DRG’s analysis of the potential impact of the launch of generic versions of Biogen’s Tecfidera (dimethyl fumarate) in the U.S. Multiple Sclerosis (MS) market. Our current model assumes generic entry in 2021, although other entry scenarios could occur (earlier or later). DRG analysts forecast the biggest impact of generic dimethyl fumarate will be on in-class brands (e.g., Vumerity). However, our research suggests that generic dimethyl fumarate will become the preferred first-line disease-modifying therapy for MS, drawing share away from other early-line mainstays. DRG’s latest forecast assumptions are summarized in this attached Market Event Summary and will be updated as these events further unfold.


Biotech set for good start to 2021

View Now